995 related articles for article (PubMed ID: 11806485)
1. Hyperglycemia and antipsychotic medications.
Haupt DW; Newcomer JW
J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
[TBL] [Abstract][Full Text] [Related]
2. Metabolic risk during antipsychotic treatment.
Newcomer JW
Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic medications: metabolic and cardiovascular risk.
Newcomer JW
J Clin Psychiatry; 2007; 68 Suppl 4():8-13. PubMed ID: 17539694
[TBL] [Abstract][Full Text] [Related]
4. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
5. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
Newcomer JW
J Clin Psychiatry; 2004; 65 Suppl 18():36-46. PubMed ID: 15600383
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents.
Henderson DC
J Clin Psychiatry; 2001; 62 Suppl 27():10-4; discussion 40-1. PubMed ID: 11806484
[TBL] [Abstract][Full Text] [Related]
7. Abnormal glucose metabolism in patients treated with antipsychotics.
Scheen AJ; De Hert MA
Diabetes Metab; 2007 Jun; 33(3):169-75. PubMed ID: 17412628
[TBL] [Abstract][Full Text] [Related]
8. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
Newcomer JW
CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
[TBL] [Abstract][Full Text] [Related]
9. [Diabetes mellitus type II--induced by "atypical" neuroleptics?].
Wetterling T
Fortschr Neurol Psychiatr; 2003 Jun; 71(6):312-22. PubMed ID: 12796851
[TBL] [Abstract][Full Text] [Related]
10. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
11. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
Monteleone P; Martiadis V; Maj M
Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
[TBL] [Abstract][Full Text] [Related]
12. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
Rzewuska M
Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
[TBL] [Abstract][Full Text] [Related]
13. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
Baptista T; Kin NM; Beaulieu S; de Baptista EA
Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
[TBL] [Abstract][Full Text] [Related]
14. The implications of weight changes with antipsychotic treatment.
Sussman N
J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S21-6. PubMed ID: 12832946
[TBL] [Abstract][Full Text] [Related]
15. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.
Silvestre JS; Prous J
Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):289-304. PubMed ID: 16082416
[TBL] [Abstract][Full Text] [Related]
16. Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity.
Van Gaal LF
Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S142-8. PubMed ID: 16863690
[TBL] [Abstract][Full Text] [Related]
17. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
Newcomer JW
J Clin Psychiatry; 2007; 68 Suppl 1():20-7. PubMed ID: 17286524
[TBL] [Abstract][Full Text] [Related]
18. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics.
Meltzer HY
J Clin Psychiatry; 2001; 62 Suppl 27():35-9; discussion 40-1. PubMed ID: 11806488
[TBL] [Abstract][Full Text] [Related]
19. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
20. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.
Citrome LL; Holt RI; Zachry WM; Clewell JD; Orth PA; Karagianis JL; Hoffmann VP
Ann Pharmacother; 2007 Oct; 41(10):1593-603. PubMed ID: 17785613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
